News•Apr 10, 2026
A NICE-Approved Treatment for 8 Million People that Fewer than 0.5% of Clinicians Offer
A new health‑tech model is delivering a NICE‑approved therapy to roughly 8 million UK patients who currently lack access, as fewer than 0.5% of clinicians prescribe it. The approach bypasses traditional hospital pathways, offering direct‑to‑consumer (DTC) prescribing and remote monitoring. Early data suggest the model can expand uptake, improve outcomes, and generate significant revenue for digital health firms. Investors are watching as the untapped market could reshape chronic‑care delivery across Europe.
